Abstract: Chondroition sulfate proteoglycans represent excellent targets for anti-tumor immunotherapy. Antibodies which target such proteoglycans can be used alone, in combinations, armed with a cytotoxic payload or unarmed. Combinations of such antibodies can target different epitopes of the proteoglycans. Internalization of the antibodies can increase the toxicity of the payloads. Single chain variable regions are especially advantageous for such anti-tumor immunotherapy.

Abstract: A compound comprising a Magainin I or Magainin II peptide wherein at least one substitution may be made for certain amino acid residues with other amino acid residues, said peptides known as substitution analogues.In addition to such substitutions, there can be included within the scope of the invention analogues wherein at least one of amino acid residues 15 and 23 may have been deleted as well, and wherein substitutions were made in the remaining peptide chain. Certain substituttion analogues within the scope of the present invention have been shown to possess increased biological activity.

Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing peptide repeating units corresponding to the 540 residue protein and also polymers containing 517 protein pentapeptides as repeating units.

Abstract: A biological reagent and diagnostic system for the detection and quantitation of endothelial plasminogen activator inhibitor (PAI) are disclosed, as are substantially pure, recombinant human endothelial PAI, its biologically pure gene and a vector for cloning the gene and expressing a gene product.

Abstract: Fragments of Factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Abstract: The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or combinations of thrombolytic agents.

Abstract: Compositions and methods for their use in modulating animal cellular responses are disclosed. The compositions include as an active agent an effective amount of an 8-substituted guanine derivative bonded 9-1' to an aldose having 5 or 6 carbon atoms in the aldose chain. The composition includes a diluent amount of a physiologically tolerable carrier. The guanine derivative is free of electrically charged functionality, while the 8-substituent has an electron withdrawing inductive effect greater than that of hydrogen and contains fewer than about 15 atoms. Animal cellular responses are modulated by contacting the cells with a composition of this invention.

Abstract: A biological reagent and diagnostic system for the detection and quantitation of endothelial plasminogen activator inhibitor (PAI) are disclosed, as are substantially pure, recombinant human endothelial PAI, its biologically pure gene and a vector for cloning the gene and expressing a gene product.

Abstract: A computer system and method are disclosed for determining a protein's tertiary structure from a primary sequence of amino acid residues. The system uses a dynamic Monte Carlo method with Metropolis sampling criterion, and a selected (2,1,0) lattice model, to simulate protein folding during the transition of the protein from an unfolded (denatured) state to its native, folded state. The system generates, for display, a folding trajectory representing successive three-dimensional images of the protein at a level of two Angstrom resolution as it folds to its native conformation. The system permits interaction between all proximate pairs of sidechains of the protein and provides faster processing through the use of the lattice.

Abstract: Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.

Abstract: A method of separating a pair of stereoisomers, and especially enantiomers, using monoclonal receptor molecules containing an antibody combining site that binds to substantially only one of that pair of stereoisomers is disclosed.

Abstract: Synthetic polypeptides whose sequences correspond substantially to amino acid residue sequences of at least portions of naturally occurring proteinoids translated from brain-specific mRNAs are disclosed as are receptors, methods and diagnostics that utilize those synthetic polypeptides. The synthetic polypeptides have molecular weights less than those of their corresponding proteinoids, and induce the production of antibodies that bind to the naturally occurring proteinoid, or a derivative thereof when bound to a carrier as a conjugate and are introduced into an animal.

Abstract: A catalytic molecule comprising a receptor molecule containing an antibody combining site that immunologically binds to a plurality of polyvalent metal ion-containing coordination complexes is disclosed. The coordination complex of a first immunoligand is kinetically inert, whereas the coordination complex of a second immunoligand is kinetically labile. The receptor molecule catalyzes a reaction of the second immunoligand. Immunogens, antigens, and methods of making and using the catalytic receptors are disclosed, as are receptor molecules that catalyze the hydrolysis of a predetermined peptide bond.

Abstract: Phosphine oxide-terminated allene-ene-yne compounds are disclosed that possess DNA-cleaving, antimicobial and tumor growth-inhibiting properties. Methods of making and using those compounds are also disclosed.

Abstract: Fragments of the factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Abstract: Preservation of leukocytes by suspending in storage medium containing modified fluid gelatin, plasma, and a non-toxic buffer. Preferred additives include heterocyclic bases which occur in nucleic acids, or nucleosides or nucleotides containing the same.

Abstract: An antibody molecule or molecule containing antibody combining site portions (catalytic molecule) that catalytically hydrolyzes a preselected carboxylic acid amide or ester bond of a reactant ligand, methods of making and using the catalytic molecule, and cells that produce those molecules are disclosed. The catalytic molecules bind to a reactant ligand containing the bond to be hydrolyzed and also to a haptenic ligand. The haptenic ligand is structurally analogous to the reactant ligand and contains a tetrahedral carbon atom that is bonded to a hydroxyl group and to a saturated carbon atom at a position in the haptenic ligand that corresponds to position of the carbonyl group and its bonded heteroatom of the reactant ligand. The haptenic ligand also contains a group that bears an ionic charge in aqueous solution at physiological pH values that is not present at a corresponding position of the reactant ligand. The ionic charge-bearing group is located in the hapten within 7 .ANG.

Abstract: A method to treat or prevent retroviral infection by administering a novel conjugate is described. Lucifer Yellow and its analogs are conjugated to compounds having carbonyl functional groups for reaction with the semicarbazide moiety of Lucifer Yellow to obtain the semicarbazone conjugate.

Abstract: An immune response-enhancing guanosine analog derivative having a structure that conforms to the formula ##STR1## wherein Z is oxygen (O) or sulfur (S); X is oxygen (O), sulfur (S) selenium (Se) or cyanimino (NCN); and R.sub.1 is an aldoglycoside is disclosed. Also disclosed are a composition containing the guanosine analog derivative as active ingredient and a method of using the composition for immunostimulation.